Publications

Rodvold KA, Gotfried MH, Isaacs RD, O'Donnell JP, and Stone E

Plasma and intrapulmonary concentrations of ETX2514 and sulbactam following intravenous administration of ETX2514SUL to healthy adult subjects

Antimicrobial Agents and Chemotherapy (2018)

Iyer R, Moussa S, Durand-Réville T, Tommasi R, and Miller A

Acinetobacter baumannii OmpA is a selective antibiotic permeant porin

ACS Infectious Diseases (2018)

McLeod SM, Shapiro AB, Moussa SH, Johnstone M, McLaughlin RE, de Jonge BLM, and Miller AA

Frequency and mechanism of spontaneous resistance to sulbactam combined with the novel β-lactamase inhibitor ETX2514 in clinical isolates of Acinetobacter baumannii

Antimicrobial Agents and Chemotherapy (2018)

Shapiro AB

Kinetics of sulbactam hydrolysis by β-lactamases, and kinetics of β-lactamase inhibition by sulbactam

Antimicrobial Agents and Chemotherapy (2017)

Shapiro AB, Gao N, Jahić H, Carter NM, Chen A, and Miller AA

Reversibility of covalent, broad-spectrum serine β-lactamase inhibition by the diazabicyclooctenone ETX2514

ACS Infectious Diseases (2017)

Durand-Réville T, et al.

ETX2514 is a broad-spectrum β-lactamase inhibitor for the treatment of drug-resistant Gram-negative bacteria including Acinetobacter baumannii

Nature Microbiology (2017)

Penwell WF, Shapiro AB, Giacobbe RA, Gu RF, Gao N, Thresher J, McLaughlin RE, Huband MD, DeJonge BLM, Ehmann DE, and Miller AA

The molecular mechanisms of sulbactam antibacterial activity and resistance determinants in Acinetobacter baumannii

Antimicrobial Agents and Chemotherapy (2015)